Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, financials
TL;DR
Cocrystal Pharma filed a routine 8-K on Jan 13, 2025. No major news.
AI Summary
Cocrystal Pharma, Inc. filed an 8-K on January 13, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.
Why It Matters
This filing indicates routine corporate reporting by Cocrystal Pharma, Inc. to the SEC, providing updates on financial statements and exhibits.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial statements and exhibits, with no indication of significant new risks or material events.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- BIOZONE PHARMACEUTICALS, INC. (company) — Former company name
- International Surf Resorts, Inc. (company) — Former company name
- January 13, 2025 (date) — Date of report
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is Cocrystal Pharma, Inc.
In which state was Cocrystal Pharma, Inc. incorporated?
Cocrystal Pharma, Inc. was incorporated in Delaware.
What is the principal executive office address for Cocrystal Pharma, Inc.?
The principal executive office address is 19805 N. Creek Parkway, Bothell, WA 98011.
What were the previous names of Cocrystal Pharma, Inc.?
Previous names of Cocrystal Pharma, Inc. include BIOZONE PHARMACEUTICALS, INC. and International Surf Resorts, Inc.
Filing Stats: 487 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-01-13 08:00:40
Filing Documents
- form8-k.htm (8-K) — 34KB
- ex99-1.htm (EX-99.1) — 40KB
- ex99-1_001.jpg (GRAPHIC) — 290KB
- ex99-1_002.jpg (GRAPHIC) — 590KB
- ex99-1_003.jpg (GRAPHIC) — 258KB
- ex99-1_004.jpg (GRAPHIC) — 300KB
- ex99-1_005.jpg (GRAPHIC) — 211KB
- ex99-1_006.jpg (GRAPHIC) — 256KB
- ex99-1_007.jpg (GRAPHIC) — 326KB
- ex99-1_008.jpg (GRAPHIC) — 311KB
- ex99-1_009.jpg (GRAPHIC) — 362KB
- ex99-1_010.jpg (GRAPHIC) — 263KB
- ex99-1_011.jpg (GRAPHIC) — 334KB
- ex99-1_012.jpg (GRAPHIC) — 294KB
- ex99-1_013.jpg (GRAPHIC) — 259KB
- ex99-1_014.jpg (GRAPHIC) — 450KB
- ex99-1_015.jpg (GRAPHIC) — 182KB
- ex99-1_016.jpg (GRAPHIC) — 337KB
- ex99-1_017.jpg (GRAPHIC) — 259KB
- ex99-1_018.jpg (GRAPHIC) — 279KB
- ex99-1_019.jpg (GRAPHIC) — 246KB
- ex99-1_020.jpg (GRAPHIC) — 350KB
- ex99-1_021.jpg (GRAPHIC) — 329KB
- ex99-1_022.jpg (GRAPHIC) — 346KB
- ex99-1_023.jpg (GRAPHIC) — 319KB
- ex99-1_024.jpg (GRAPHIC) — 210KB
- ex99-1_025.jpg (GRAPHIC) — 198KB
- ex99-1_026.jpg (GRAPHIC) — 200KB
- ex99-1_027.jpg (GRAPHIC) — 235KB
- 0001493152-25-001870.txt ( ) — 11287KB
- cocp-20250113.xsd (EX-101.SCH) — 3KB
- cocp-20250113_def.xml (EX-101.DEF) — 29KB
- cocp-20250113_lab.xml (EX-101.LAB) — 33KB
- cocp-20250113_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 13, 2025 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer